ACADIA Pharmaceuticals Inc. vs HUTCHMED (China) Limited: Annual Revenue Growth Compared

Biopharma Revenue Race: ACADIA vs. HUTCHMED

__timestampACADIA Pharmaceuticals Inc.HUTCHMED (China) Limited
Wednesday, January 1, 201412000091813000
Thursday, January 1, 201561000178203000
Friday, January 1, 201617331000216080000
Sunday, January 1, 2017124901000241203000
Monday, January 1, 2018223807000214109000
Tuesday, January 1, 2019339076000204890000
Wednesday, January 1, 2020441755000227976000
Friday, January 1, 2021484145000356128000
Saturday, January 1, 2022517235000426409000
Sunday, January 1, 2023726437000837999000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biopharma Giants: Revenue Growth from 2014 to 2023

In the dynamic world of biopharmaceuticals, revenue growth is a key indicator of a company's success and market influence. Over the past decade, ACADIA Pharmaceuticals Inc. and HUTCHMED (China) Limited have showcased contrasting trajectories in their annual revenue growth. Starting in 2014, ACADIA's revenue was modest, but by 2023, it had skyrocketed by over 6,000%, reflecting a robust expansion strategy and successful product launches. In contrast, HUTCHMED's revenue growth, while steady, was more gradual, increasing by approximately 800% over the same period. This divergence highlights ACADIA's aggressive market penetration compared to HUTCHMED's steady, yet slower, growth. The data underscores the importance of strategic planning and market adaptation in the biopharmaceutical industry, where rapid innovation and competition are the norms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025